During the past decade, Centro Oncológico de Panamá conducted 4 clinical trials. In the 10-year time frame, 4 clinical trials started and 2 clinical trials were completed, i.e. on average, 50% percent of trials that started reached the finish line to date. In the past 5 years, 1 clinical trials started and 2 clinical trials were completed. i.e. 200% of trials that started reached the finish line.

According to Clinical.Site data, the most researched conditions in "Centro Oncológico de Panamá" are "Cervical Cancer" (2 trials), "HER2-Positive Early Breast Cancer" (1 trials) and "Triple Negative Breast Cancer" (1 trials). Many other conditions were trialed in "Centro Oncológico de Panamá" in a lesser frequency.

Most popular intervention types in "Centro Oncológico de Panamá" are "Drug" (4 trials). Other intervention types were less common.

The name of intervention was led by "Atezolizumab" (1 trials), "Atezolizumab (MPDL3280A), an engineered anti-PDL1 antibody" (1 trials), "Bevacizumab" (1 trials), "Carboplatin" (1 trials) and "Nab-Paclitaxel" (1 trials). Other intervention names were less common.

The vast majority of trials in "Centro Oncológico de Panamá" are 2 trials for "All" genders and 2 trials for "Female" genders.

Currently, there are NaN active trials in "Centro Oncológico de Panamá". undefined are not yet recruiting, undefined are recruiting, 1 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 3 completed trials in Centro Oncológico de Panamá, undefined suspended trials, and undefined terminated clinical trials to date.

Out of the total trials that were conducted in Centro Oncológico de Panamá, 0 "Phase 1" clinical trials were conducted, 3 "Phase 2" clinical trials and 1 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".